1. Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with risk for thromboembolic complications and mortality in patients with COVID-19. (14th October 2021) Authors: Luo, S; Samelko, B; Du-Fay-De-Lavallaz, J M; Gomez, J M D; Zemke, A M; Suboc, T; Williams, K A; Fugar, S; Simmons, J A; Volgman, A S; Hayek, S; Reiser, J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗